The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy
Abstract
OBJECTIVES: To determine the protective efficacy of highly active antiretroviral therapy (HAART) against AIDS dementia complex (ADC) relative to other initial AIDS-defining illnesses (ADIs), Australian AIDS notification data over recent years were examined. METHODS: All initial ADIs in Australia over the period 1992-1997 were included. Three initial ADI groups were established: ADC; other predominantly central nervous system (CNS) ADIs (toxoplasmosis and cryptococcosis); and non-CNS ADIs. For each ADI grouping, the proportion of total ADls, and median CD4 cell count in the pre-HAART era (1992-1995) were compared with the HAART era (1996 and 1997). RESULTS: Initial ADls peaked in Australia in 1994 (n = 1049), with a gradual decline to 1996 (n = 722), and a marked decline in 1997 (n = 367). ADC constituted 4.4% of initial ADIs over the period 1992-1995, but increased after the introduction of HAART to 6.0% in 1996 and 6.5% in 1997 (P = 0.02). In contrast, the proportion of other CNS ADIs (1992-1995, 8.1%; 1996, 6.0%; 1997, 8.2%; P = 0.41) was stable over the period 1992-1997. The median CD4 cell count at ADC diagnosis increased from 70/mm3 in 1992-1995 to 120/mm3 in 1996 and 170/mm3 in 1997 (P = 0.04). Although the median CD4 cell count also increased significantly over this period for both other CNS ADIs (40-60/mm3; P = 0.02), and non-CNS ADIs (60-70/mm3; P = 0.02), the increase was small. CONCLUSION: A proportional increase in ADC compared with other ADIs and a marked increase in the median CD4 cell count at ADC diagnosis have occurred since the introduction of HAART in Australia. These changes suggest that HAART has a lesser impact on ADC than on other ADIs, with the poor CNS penetration of many antiretroviral agents a possible explanation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
A wilcoxon‐type test for trend
Cuzick, J. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040112 · Cited by 1,900
Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610103351501 · Cited by 1,091
Flexner, C. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381808 · Cited by 852
Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy
Hogg, R. S. (1998) · JAMA · doi:10.1001/jama.279.6.450 · Cited by 850
Egger, M., Hirschel, B., Francioli, P., Sudre, P., Wirz, M., Flepp, M., Rickenbach, M., Malinverni, R., Vernazza, P., & Battegay, M. (1997) · BMJ · doi:10.1136/bmj.315.7117.1194 · Cited by 615
Darbyshire, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)05387-1 · Cited by 509
Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy
Brodt, H. R., Kamps, B. S., Gute, P., Knupp, B., Staszewski, S., & Helm, E. B. (1997) · AIDS · doi:10.1097/00002030-199714000-00010 · Cited by 411
Clinical Manifestations of AIDS in the Era of Pneumocystis Prophylaxis
Hoover, D. R., Saah, A. J., Bacellar, H., Phair, J., Detels, R., Anderson, R., & Kaslow, R. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312233292604 · Cited by 406
Cited by
Updated research nosology for HIV-associated neurocognitive disorders
Antinori, A., Arendt, G., Becker, J. T., Brew, B. J., Byrd, D. A., Cherner, M., Clifford, D. B., Cinque, P., Epstein, L. G., Goodkin, K., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000287431.88658.8b · Cited by 2,630
Self-citationPathways to neuronal injury and apoptosis in HIV-associated dementia
Kaul, M., Garden, G. A., & Lipton, S. A. (2001) · Nature · doi:10.1038/35073667 · Cited by 1,210
HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998
Sacktor, N., Lyles, R. H., Skolasky, R., Kleeberger, C., Selnes, O. A., Miller, E. N., Becker, J. T., Cohen, B., McArthur, J. C., & Study*, T. M. A. C. (2001) · Neurology · doi:10.1212/wnl.56.2.257 · Cited by 591
HIV and antiretroviral therapy in the brain: neuronal injury and repair
Ellis, R., Langford, D., & Masliah, E. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2040 · Cited by 517
Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons
RIPPETH, J. D., HEATON, R. K., CAREY, C. L., MARCOTTE, T. D., MOORE, D. J., GONZALEZ, R., WOLFSON, T., GRANT, I., & GROUP, T. H. (2004) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617704101021 · Cited by 435
Metadata
- Authors
- Dore, G. J., Correll, P. K., Li, Y., Kaldor, J. M., Cooper, D. A., & Brew, B. J.
- Venue
- AIDS
- Published
- 1999-07
- Volume
- 13
- Issue
- 10
- Pages
- 1249-1253
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2030188343
- Cited by
- 413
- References
- 17
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. https://app.cochat.ai/papers/10.1097/00002030-199907090-00015
- The paper
- Dore, G. J., Correll, P. K., Li, Y., Kaldor, J. M., Cooper, D. A., & Brew, B. J. (1999). Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. https://doi.org/10.1097/00002030-199907090-00015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.